How better blood sugar control changes HDL cholesterol in people with type 1 diabetes
Studies HDL cholesterol in adults with type 1 diabetes as blood sugar control improves.
Plain-language title generated from the registry record
Registry title: The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes
Key facts
- Where
- Dijon, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes whose blood sugar is poorly controlled, and also healthy adults without diabetes or lipid problems as a comparison group.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 1 diabetes group: treated type 1 diabetes with HbA1c above 8.0% (above 64 mmol/mol). Control group: no diabetes and no lipid problems.
- Earlier treatment
- Type 1 diabetes group: treated with insulin, and cannot have started lipid-lowering therapy within the month before the study. Control group: no diabetes medicine and no lipid-lowering medicine.
- Biomarker or test result
- Control group: fasting blood glucose below 1,10 g/L, triglycerides below 1,50 g/L, LDL cholesterol below 1,60 g/L, and HDL cholesterol above 1,03 mmol/L (40 mg/dL) (men) or above 1,30 mmol/L (50 mg/dL) (women). Type 1 diabetes group: HbA1c above 8.0% (64 mmol/mol).
Main reasons for not taking part
- Pregnant, in labor or breastfeeding women
- Systemic inflammatory disease
- Immunosuppressive or long-term corticosteroid medicines
- Type 1 diabetes group: diagnosed within the last 12 months, kidney function (CKD-EPI) below 60 mL/min/1.73 m², or albuminuria 30 mg/g creatinine or more
- Control group: cardiovascular disease, kidney disease or metabolic syndrome
Read by machine on 12 November 2026.
Where in France
- Chu Dijon BourgogneDijon, FranceContact: Benjamin BOUILLETTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Trial code
- NCT07564752
- Record updated
- 4 May 2026
- Original description
The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank.Read full original descriptionShow less
Effect of Improved Glycemic Control on the Composition and Function of High-density Lipoproteins (HDL) in Patients With Type 1 Diabetes: a Prospective, Single-center Study. Comparison With Non-diabetic, Non-dyslipidemic Control Subjects. - HAGI-T1D Study
The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank.
T1D patients hospitalized in the Endocrinology-Diabetology-Metabolic Diseases Department at the Dijon Bourgogne University Hospital for poorly controlled diabetes (defined by glycated hemoglobin HbA1c >8.0%).
The study includes a T1D group of 80 patients with unsatisfactory glycemic control, who will undergo intensified therapy in accordance with standard clinical practice (modification of insulin therapy, therapeutic education, and lifestyle and dietary guidelines). The study also includes a control group of 63 non-diabetic, non-dyslipidemic subjects enrolled based on the results of laboratory tests from the screening visit to assess whether improved glycemic control in the T1D group restores anti-atherogenic functions and HDL composition to a level comparable to that of the control group.
Inclusion: Control group non-diabetic and non-dyslipidemic :; A person who has giver written consent; Fasting blood glucose < 1,10 g/L; Triglycerides < 1,50 g/L (< 1,70 mmol/L); HDL cholesterol > 1,03 mmol/L (men) or > 1,30 mmol/L (women); LDL cholesterol < 1,60 g/L; Type 1 diabetes group :; A person who has giver written consent; Treated type 1 diabetes (regardless of the route of insulin administration); HbA1c > 8.0% (> 64 mmol/mol).
Exclusion: Medications that affect lipoprotein metabolism: immunosuppressive therapy, long-term corticosteroid therapy; Control group non-diabetic and non-dyslipidemic :; Dyslipidemia or use of lipid-lowering medication; Diagnosis of type 1 diabetes within 12 months prior to enrollment; Initiation of lipid-lowering therapy within the month prior to the study; Initiation of lipid-lowering therapy during the 3 months of the study; Systemic inflammatory disease; Diabetes or use of an antidiabetic medication; Cardiovascular disease (history of stroke, myocardial infarction, coronary artery disease); Kidney disease (glomerular filtration rate CKD-EPI < 75 mL/min/1.73 m²); Type 1 diabetes group:; Presence of metabolic syndrome defined by the presence of at least three of the following criteria (NCEP-ATP III criteria):; waist circumference > 102 cm in men, > 88 cm in women; fasting triglycerides > 1.70 mmol/L ( > 1.50 g/L); HDL cholesterol > 1.03 mmol/L in men and 1.29 mmol/L in women; systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg; fasting blood glucose ≥ 6.10 mmol/L (≥ 1.10 g/L); Type 1 diabetes group:; Albuminuria ≥ 30 mg/g creatinine; All participants :; A person who is not enrolled in or eligible for a social security program; A person subject to a legal protective measure (guardianship, tutorship); A person subject to a judicial protective measure; Pregnant women, women in labor, or breastfeeding women; Adults who are legally incompetent or unable to give informed consent; Minors; Glomerular filtration rate (CKD-EPI) < 60 mL/min/1.73 m².